Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Myelodysplastic Syndromes | Current Treatment: Physician Insights | US | 2020

Login to access report north_east
Contact sales account_box

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia. Treatment goals vary according to disease severity, and patients may receive drugs such as erythropoietin-stimulating agents (ESAs), lenalidomide, and hypomethylating agents (HMAs). However, the MDS treatment landscape is set to change dramatically with the launch of several new emerging therapies. We explore current prescribing patterns, factors that drive or constrain hematologists’ use of key therapies, and the changes in prescribing expected in the coming year.

QUESTIONS ANSWERED

  • What percentage of MDS patients progress from one line of therapy to another based on severity? What is the treatment duration before progressing? What factors move patients through lines of therapy?
  • Which is the preferred drug for lower-risk MDS patients who do not respond to ESAs? What is physicians’ preference for the different HMAs? What is the use of lenalidomide (Revlimid) across different lower-risk MDS patient groups?
  • How does MDS treatment vary for patients demonstrating different prognosis scores?
  • How has the use of MDS therapy changed over time? What are the reasons for increased or decreased use of various agents for the treatment of MDS?

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

CONTENT HIGHLIGHTS

Release date: May 2020

Geographies: United States

Primary Research: Survey of 97 U.S. hematologists

Key Drugs Covered: ESAs, lenalidomide, azacitidine, decitabine

Key insights provided

  • Factors influencing disease management and treatment decisions
  • Drivers and constraints of treatment selection
  • Physician-reported treatment practices and brand-level patient shares
  • Rationale for changes in treatment approach
  • Physician insight on persistency and compliance
  • Physician-reported recent/anticipated changes in brand usage or treatment approach
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east